Please check your internet connection and try again.
# Hyoscine Butylbromide (Buscopan)
## Overview
A quaternary ammonium anticholinergic/antispasmodic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier significantly, resulting in fewer central nervous system (CNS) side effects.
## Primary Indications
Symptomatic relief of gastrointestinal (GI) spasms, irritable bowel syndrome (IBS), and biliary/urinary tract spasms. Used in palliative care for "death rattle" (secretions management).
## Adult Dosing
* **Oral:** 10 mg to 20 mg three to four times daily. Maximum: 100 mg/day.
* **IV/IM/SC:** 20 mg as a single dose; may be repeated after 30 minutes if necessary. Maximum: 100 mg/day.
* **Palliative Care (Secretions):** 20 mg SC q4h PRN or 60–120 mg/24h via continuous subcutaneous infusion (CSCI). *Note: Dosing varies by local palliative protocol.*
## Pediatric Dosing
* **Children 6–12 years:** 10 mg (one tablet) three times daily.
* **Not recommended** for children under 6 years without specialist oversight.
* *Note: IV/IM dosing in pediatrics is off-label and varies significantly by weight/indication; consult local pediatric formulary guideline.*
## Dose Adjustments
* **Renal/Hepatic Impairment:** Use with caution. No standardized formal dose reduction protocol exists, but lower starting doses and longer intervals are prudent.
* **Elderly:** Use caution due to increased sensitivity to anticholinergic effects (e.g., urinary retention, constipation).
## Contraindications
* Hypersensitivity to the active substance or excipients.
* Myasthenia gravis.
* Mechanical intestinal obstruction or paralytic ileus.
* Megacolon.
* Narrow-angle glaucoma.
* Tachycardia/Tachyarrhythmias.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
Common side effects are anticholinergic:
* Dry mouth
* Visual disturbances (tachycardia/blurred vision)
* Constipation
* Urinary retention
* Infrequent but serious: Anaphylaxis/anaphylactoid reactions, tachycardia.
## Key Drug Interactions
* **Anticholinergics:** Additive effects (e.g., antihistamines, tricyclic antidepressants).
* **Dopamine Antagonists:** May result in antagonized effects on GI motility (e.g., metoclopramide).
* **Tachycardia-inducing agents:** Beta-agonists/anticholinergics may exacerbate tachycardia.
## Monitoring
* Monitor heart rate (risk of tachycardia).
* Assess for relief of spasm.
* Monitor for signs of urinary retention or severe constipation.
* In palliative settings, monitor for efficacy of secretion control and side effects.
## Clinical Pearls
* **Poor Bioavailability:** Oral absorption is low; IV/IM route is significantly more effective for acute, severe spasms.
* **CNS profile:** Buscopan is a quaternary ammonium compound; it does not produce the sedation or confusion associated with hyoscine hydrobromide (scopolamine).
* **Avoid in diagnostic use:** Do not use if the cause of abdominal pain is unclear or if symptoms of acute abdomen (fever, rebound tenderness) are present.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Dosing may vary based on institutional protocols, local guidelines, and patient-specific factors. Always verify the current prescribing information via the manufacturer's data sheet or a trusted formulary before administration.*
